Golimumab Phase 3 Data Show Significant Improvement In Physical Function In Patients with Rheumatoid... (ectualproperty protection current and fu...)

(Date:5/21/2013)... Raleigh, NC (PRWEB) May 21, 2013 ... and financial services company for clinical trials, announced ... Aggregate Spend Solutions, LLC. Clinverse’s ClinPay® FLS ... automated investigator payment process. SpendMD ™, ... only complete solution for tracking and reporting transfer ...

(Date:5/21/2013)... 21, 2013 Smarter Security, Inc., provider ... today announced that Genzyme, a Sanofi company and leading ... Detective® CL for a multi-use facility in the United ... other Genzyme buildings, this latest order underscores the satisfaction ... tailgate detection device improving doorway access control. ...

(Date:5/21/2013)... ALBANY, New York , May 21, 2013 /PRNewswire/ ... published by Transparency Market Research ( http://www.transparencymarketresearch.com ) "Biochip ... Science Research, IVD Tests) - U.S. Industry Analysis, Size, Share, ... USD 2.4 billion in 2011 and is expected to ... 2018, to reach an estimated value of USD 4.7 ...

(Date:5/21/2013)... May 21, 2013 As the ... strong push within the industry to deliver better ... Organizations and pharma companies often means turning big ... Microtablets, developed in collaboration with Sensidose AB and ... can bring products to market sooner. The partnership ...

Breaking Biology Technology:Clinverse, Inc. Announces Strategic Alliance with Aggregate Spend Solutions, LLC 2 Clinverse, Inc. Announces Strategic Alliance with Aggregate Spend Solutions, LLC 3 Door Security at Genzyme, a Sanofi Company, Enhanced with Door Detective from Smarter Security 2 Door Security at Genzyme, a Sanofi Company, Enhanced with Door Detective from Smarter Security 3 The U.S. Biochip Products and Services Market is Expected to Reach USD 4.7 Billion in 2018: Transparency Market Research 2 The U.S. Biochip Products and Services Market is Expected to Reach USD 4.7 Billion in 2018: Transparency Market Research 3 The U.S. Biochip Products and Services Market is Expected to Reach USD 4.7 Billion in 2018: Transparency Market Research 4 The U.S. Biochip Products and Services Market is Expected to Reach USD 4.7 Billion in 2018: Transparency Market Research 5 The Development of an Innovative Microtablet Dosage Form, a Success Story: Live Webinar Hosted by Xtalks 2

[0] Clinverse, Inc. Announces Strategic Alliance with Aggregate Spend Solutions, LLC [0] Door Security at Genzyme, a Sanofi Company, Enhanced with Door Detective from Smarter Security [0] The U.S. Biochip Products and Services Market is Expected to Reach USD 4.7 Billion in 2018: Transparency Market Research [0] The Development of an Innovative Microtablet Dosage Form, a Success Story: Live Webinar Hosted by Xtalks

... Oncolytics Biotech Inc.,("Oncolytics") (TSX:ONC, NASDAQ:ONCY) announced today ... review, the Company is initiating a U.S.,Phase ... REOLYSIN(R) in,combination with paclitaxel and carboplatin in ... K-RAS or EGFR-activated tumours. The Principal,Investigator is ...

... /PRNewswire-FirstCall/ - OncoGenex,Pharmaceuticals, Inc. (NASDAQ: OGXI ... that it has granted to Eagle Pharmaceuticals, ... commercialize TOCOSOL(R),Paclitaxel. Under the terms of the ... from future TOCOSOL Paclitaxel sales and a,percentage ...

... Germany, Sept. 1 ,Boston Scientific Corporation (NYSE: ... its landmark SYNTAX trial comparing percutaneous coronary ... Stent,System to contemporary coronary artery bypass graft ... significant differences,between PCI and CABG in rates ...

Cached Biology Technology:/R E P E A T -- Oncolytics Biotech Inc. Announces U.S. Phase 2 Combination Clinical Trial for Non-Small Cell Lung Cancer Patients with K-RAS or EGFR-Activated Tumours/ 2 /R E P E A T -- Oncolytics Biotech Inc. Announces U.S. Phase 2 Combination Clinical Trial for Non-Small Cell Lung Cancer Patients with K-RAS or EGFR-Activated Tumours/ 3 /R E P E A T -- Oncolytics Biotech Inc. Announces U.S. Phase 2 Combination Clinical Trial for Non-Small Cell Lung Cancer Patients with K-RAS or EGFR-Activated Tumours/ 4 OncoGenex Pharmaceuticals announces out-license of TOCOSOL Paclitaxel to Eagle Pharmaceuticals 2 OncoGenex Pharmaceuticals announces out-license of TOCOSOL Paclitaxel to Eagle Pharmaceuticals 3 Landmark SYNTAX Trial Reports Comparable Safety Outcomes for Complex Patients Treated With TAXUS(R) Express2(TM) Stents or Bypass Surgery 2 Landmark SYNTAX Trial Reports Comparable Safety Outcomes for Complex Patients Treated With TAXUS(R) Express2(TM) Stents or Bypass Surgery 3 Landmark SYNTAX Trial Reports Comparable Safety Outcomes for Complex Patients Treated With TAXUS(R) Express2(TM) Stents or Bypass Surgery 4 Landmark SYNTAX Trial Reports Comparable Safety Outcomes for Complex Patients Treated With TAXUS(R) Express2(TM) Stents or Bypass Surgery 5

/R E P E A T -- Oncolytics Biotech Inc. Announces U.S. Phase 2 Combination Clinical Trial for Non-Small Cell Lung Cancer Patients with K-RAS or EGFR-Activated Tumours/OncoGenex Pharmaceuticals announces out-license of TOCOSOL Paclitaxel to Eagle Pharmaceuticals Landmark SYNTAX Trial Reports Comparable Safety Outcomes for Complex Patients Treated With TAXUS(R) Express2(TM) Stents or Bypass Surgery

(Date:5/21/2013)... 21, 2013 Royal Philips Electronics (NYSE: PHG, ... first portable ultrasound with Philips, industry leading Live 3D ... CX50 xMATRIX with available Live 3D TEE and ICE ... at the EuroPCR, official meeting for the European Association ... Since its launch in 2012, Philips CX50 xMATRIX has ...

(Date:5/21/2013)... the way genes function without changing the underlying ... blood of pregnant women during any trimester, potentially ... the weeks after giving birth, and an opportunity ... findings of the small study involving 52 pregnant ... Molecular Psychiatry . , "Postpartum depression can be ...

(Date:5/20/2013)... also commonly resistant to antimicrobial substances made by ... mBio , the online open-access journal of ... and host antimicrobials LL-37 and lysozyme, which help ... that patients with life-threatening multi-drug resistant infections are ... is a last-line drug for treating several kinds ...

Breaking Biology News(10 mins):Philips CX50 xMATRIX now offers world-class interventional and diagnostic features on single portable system 2 Genetic predictors of postpartum depression uncovered by Hopkins researchers 2 Genetic predictors of postpartum depression uncovered by Hopkins researchers 3 Resistance to last-line antibiotic makes bacteria resistant to immune system 2 Resistance to last-line antibiotic makes bacteria resistant to immune system 3

[0] Philips CX50 xMATRIX now offers world-class interventional and diagnostic features on single portable system [0] Genetic predictors of postpartum depression uncovered by Hopkins researchers [0] Resistance to last-line antibiotic makes bacteria resistant to immune system

... "Basic science and clinical medicine move at different pace ... strategies to manage cancer patients. We need to efficiently translate ... in the clinic." Sherene Loi and Fabrice Andr, ... four major areas: , Molecular pathology, the roots ...

... award-winning research project, funded by the British Heart Foundation (BHF), ... how doctors predict a patient,s risk of having a heart ... a BHF Centre of Research Excellence, in collaboration with the ... of combining PET and CT scanning to image the disease ...

... Mass. A team of kinesiology researchers led by ... recently received a 2.5-year, $975,000 grant through the Navy ... study how the average 100-lb. equipment load carried by ... affects their survivability, likelihood of injury and ability to ...

Cached Biology News:Fourth IMPAKT Breast Cancer Conference 2 Fourth IMPAKT Breast Cancer Conference 3 Scientists develop new technique that could improve heart attack prediction 2 Kinesiology team gets $975,000 Defense grant to study effects of heavy loads on soldiers 2

Fourth IMPAKT Breast Cancer Conference Scientists develop new technique that could improve heart attack prediction Kinesiology team gets $975,000 Defense grant to study effects of heavy loads on soldiers

... coating using advanced automated high throughput microplate processing equipment that ... also accommodate virtually any lot size of the following formats ... 8 and 12 well strips, ... 384 well microplate, ...

...

... Mynox is the first biological ... killing them, and not just ... the only anti-mycoplasma agent that ... virus stocks directly. The cytotoxicity ...

Mynox is intended for research use only. Mynox is used for the elimination of Mycoplasma and Acholeplasma in cell and virus cultures, and other biologicals....

Biology Products:

Microplate Coating Services from Affinity Life Sciences, Inc Cytomics FC 500 Series Flow Cytometry Systems from Beckman Coulter Mynox Mycoplasma Elimination Reagent from Minerva Biolabs GmbH Mynox Mycoplasma Elimination Reagent from Sigma-Aldrich